Rifampicin resistance among patients with Tuberculosis at the Olabisi Onabanjo University Teaching Hospital, Sagamu

  • Olusoji J Daniel Department of Community Medicine and Primary Care, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria
  • Janet Olufisayo Bamidele http://orcid.org/0000-0003-1852-7540
  • John Kolawole Sodeinde
  • Adeola Adebayo Ekundayo
  • Adekunle Albert Salako
Keywords: Gene Xpert, Drug resistance, Rifampicin Resistance, Tuberculosis


Background: Tuberculosis (TB) is a major public health problem in Nigeria. The emergence of multidrug-resistant Tuberculosis poses a threat to global Tuberculosis control and if not effectively addressed, may wipe out the achievements of previous efforts in controlling Tuberculosis.

Objectives: To determine the prevalence and factors associated with rifampicin resistance amongpatients receiving care for TB at the OlabisiOnabanjo University Teaching Hospital, Sagamu.

Methods: A retrospective study of presumptive Tuberculosis cases managed between January 2013 and December 2016 at the Directly Observed Treatment clinic, OlabisiOnabanjoUniversity Teaching Hospital Sagamu, Ogun State, Nigeria,was done. One sputum sample was obtained from each patient for the Gene Xpert® test to diagnoseTB and to determine rifampicin resistance among patients with confirmed Mycobacterium tuberculosis infection. HIV screening  was also  carried out on all the patients using HIV Rapid Test kits. The sociodemographic data were retrieved from the presumptive Tuberculosis register.

Results: A total of 1572 presumptive TB patients were screened for TB, out of which 187 (11.8%) were confirmed to be infected with Mycobacterium tuberculosis (MTB). A total of 20 (10.7%) of the 187 MTB patients had rifampicin resistance using Gene Xpert® method. Rifampicin resistance rate was significantlyassociated with re-treatment TB category but not with age, sex or HIV status.

Conclusion: The study showed rifampicin drug resistance among confirmed TB patients. There is a need to decentralizethe use of  Gene Xpert® test for TB to the peripheral facilities and make it a point of care test for presumptive TB patients.



WHO 2016. What is TB? How is it treated? Available at www.who.int/features/qa/08/en/ Accessed on 05/01/2016

WHO 2016. Global Tuberculosis Report. Available at www.who.int/tb/publicaations/global_report/en/ Accessed on 05/01/2016

Federal republic on Nigeria. Guidelines for programmatic and clinical management of drug resistant TB in Nigeria 2015. Available at stoptbng.org/…/2015. Accessed on 08/02/2016

Federal Ministry of Health: National Tuberculosis and Leprosy Control Program. National TB Prevalence Survey Report 2014

US Department of State 2012. Nigeria Tuberculosis Fact Sheet. Available at www.photos.state.gov/libraries/nigeria/.../january

Sharma SK, Mohan A. Multidrug-resistant tuberculosis. Indian J Med Res. 2004;120:354–76

Sunita T, Rajesh K, Surya DS. Prevalence of Multidrug Resistant Pulmonary Tuberculosis in North Bihar. J ClinDiagn Res. 2015 ;9(11):LC09-12

Andrews JR, Gandhi NR, Moodley P, Shah NS, Sturm AW, et al. Exogenous Reinfection as a Cause of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Rural South Africa. The Journal of Infectious Diseases.2008;198(11):1582–89.

Agarwal AK, Chugh IM, Shah A. Multidrug resistant tuberculosis : successful treatment with an unconventional regimen. Ind J Tub.1998;45:227

Sharma SK, Kumar S, Saha PK, George N, Arora SK, Gupta D, et al. Prevalence of multidrug-resistant tuberculosis among Category II pulmonary tuberculosis patients. Indian J Med Res. 2011;133:312–15).

Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/ KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, SouthAfrica.Clin Infect Dis. 2007;45:1409–14.

World Health Organization 2010. WHO endorses new rapid tuberculosis test. Available at www.who.int/mediacentre/news/releases/2010/ . Accessed on 04/01/2016

WHO. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF. Policy statement. 2011; [PubMed]

Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lance. Lancet Publishing Group; 2011;377: 1495–1505. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3085933&tool=pmcentrez&rendertype=abstract[PMC free article][PubMed]

Nwadioha SI, Nwookedi EOP, Ezema GC, Eronini GC, Eronini NC, Anikwe A, Audu F, et al. drug resistant Mycobacterium Tuberculosis in Benue, Nigeria. Br Microbiol Res J 2014. 2014;4(9):988-995

Gambo Aliyu,Samar S. El-Kamary,Alash’le Abimiku, Nicholas Ezati, Iwakun Mosunmola, Laura Hungerford, Clayton Brown, Kathleen J Tracy, Joshua Obasanya and William Blathner. Mycobacterial Etiology of Pulmonary Tuberculosis and association with HIV infection and multidrug Resistance in Northern Nigeria. Tb research and Treatment vol2013, Article ID 650561 9pages

Farazi A, Sofian N, Katebi F, Hoseini SD, Kashavarz R, Caspian. J Int Med 2013 Fall;4(4):785-9

Yang Y, Zhou C, Shi L, Meng H, Yan H. Prevalence And Characterization Of Drug Resistant Tuberculosis In A Local Hospital In Northeast China. Int J Infec Dis 2014 May;22():85-6

Yakoob M, Sharana M, Melendhran P, Lise Werner, Koleka M. Rifampicin Mono-Resistance in Mycobacterium tuberculosis in Kwazulu-Natal, South Africa: A Significant Phenomenom in a High Prevalence TB-HIV Region. Journals.plos.org.2013.accessed 31/10/2017

Yang X, Li Y, Wen X, Wu X and Li X. Risk Factors for Drug Resistance in Pulmonary Tuberculosis in Patients. JEMB 2010;3,162-167

Faustini A, Hall A J and Perucci C A. Risk Factors for MultiDrug Resistant Tuberculosis in Europe. A Systemic Review. Thorax 2006;61,158-163

Lomtadze N, Aspindzelasvili R, Janjgava M, Mirtskhulava V, Wright A, Blumbery H M and Salakaia A. Prevalence and Risk Factors for MultiDrug Resistant Tuberculosis in Republic of Georgia: A Population Based Study. The International Journal of TB and Lung Disease 2009;13:68-73

Liu Y, Zhu L, Shao Y, Song H, Li G, Zhon Y, et al. Rates and Risk Factors of Drug Resistant Tuberculosis in Northeastern China. BMC Public Health 2013;13:1171

Out A, Umoh V, Habib A, Ameh S, Lawsun L, Ansa V. drug Resistance Among Pulmonary Tuberculosis Patients in Calabar Nigeria. PubMed 2013;2013:1-6

Abdella K, Abdissa K, Kebede W, Abebe G. Drug Resistance Patterns of Mycobacterium Tuberculosis Complex and associated factors among retreatment cases around Jimma SouthEast Ethiopia. BMC Public Health 2015 Jul 2;15():599

Mulu W, Mekonnen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. Afr Health Sci. 2015 Jun; 15(2):368-77.

Range N, Friis H, Mfaume S, Magnussen P, Chanualucha J, Kilale A, Mugomela A, Andersen AB. Anti-tuberculosis drug resistance pattern among pulmonary tuberculosis patients with or without HIV infection in Mwanza, Tanzania. Tanzan J Health Res. 2012 Oct; 14(4):243-9.

Aguiar F, Vieira MA, Staviack A, Buarque C, Marsico A, Fonseca L, Chaisson R, Kristski A, Werneck G, Mello F. Prevalence of anti-tuberculosis drug resistance in an HIV/AIDS reference hospital in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis. 2009 Jan; 13(1):54-61.

Original Research